Yesterday when Tweed released Bedica 17/0, I'm almost certain it was listed at $7.50. I thought strange because of Bedrocans $5 cap. That lead me to believe Tweed was taking a margin for retail.
Today, it's listed at $5. So now I'm not sure if I had something in my eye and didn't see it right, or that someone called them out on it.
I think it's the right move to stock Bedrocan strains and Bedrocan prices because folks have a synergistic impression of the two companies.
The only justified price difference I can anticipate going forward is between taxes charged on RecMj and MedMJ. If Bedrocan takes the helm fully on MedMJ and Tweed for RecMJ, there is where I can see a reasonable price difference.